Routine Reflux Testing Guides Timely Antireflux Treatment to Reduce Acute and Chronic Rejection After Lung Transplantation

被引:8
|
作者
Lo, Wai-Kit [1 ,2 ,3 ]
Goldberg, Hilary J. [3 ,4 ]
Sharma, Nirmal [3 ,4 ]
Wee, Jon O. [3 ,5 ]
Chan, Walter W. [1 ,3 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA
[2] Boston VA Healthcare Syst, Div Gastroenterol, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA
[5] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA USA
关键词
BRONCHIOLITIS OBLITERANS SYNDROME; EARLY ALLOGRAFT INJURY; GASTROESOPHAGEAL-REFLUX; IMPEDANCE MEASURES; SURGERY; PRETRANSPLANT; ASPIRATION; DISEASE; FUNDOPLICATION; THERAPY;
D O I
10.14309/ctg.0000000000000538
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Gastroesophageal reflux has been associated with poorer lung transplantation outcomes, although no standard approach to evaluation/management has been adopted. We aimed to evaluate the effect of timely antireflux treatment as guided by routine reflux testing on postlung transplant rejection outcomes.METHODS: This was a retrospective cohort study of lung transplant recipients at a tertiary center. All patients underwent pretransplant ambulatory pH monitoring. Timely antireflux treatment was defined as proton pump inhibitor initiation or antireflux surgery within 6 months of transplantation. Patients were separated into 3 groups: normal pH monitoring (-pH), increased reflux (+pH) with timely treatment, and +pH with delayed treatment. Rejection outcomes included acute rejection, bronchiolitis obliterans syndrome, and chronic lung allograft dysfunction per International Society for Heart and Lung Transplantation criteria. Time-to-event analyses using Cox proportional hazard models were applied. Patients not meeting outcomes were censored at death or last clinic visit.RESULTS: One hundred seventy-five patients (59% men/mean 56.3 yr/follow-up: 496 person-years) were included. On multivariable analyses, +pH/delayed treatment patients had higher risks of acute rejection (adjust hazard ratio [aHR]:3.81 [95% confidence interval [CI]: 1.90-7.64], P = 0.0002), bronchiolitis obliterans syndrome (aHR: 2.22 [95% CI: 1.07-4.58], P = 0.03), and chronic lung allograft dysfunction (aHR: 2.97 [95% CI: 1.40-6.32], P = 0.005) than +pH/timely treatment patients. Similarly, rejection risks were increased among +pH/delayed treatment patients vs -pH patients (all P < 0.05). No significant differences in rejection risks were noted between +pH/timely treatment patients and -pH patients. Failure/complications of antireflux treatment were rare and similar among groups.DISCUSSION: Timely antireflux treatment, as directed by pretransplant reflux testing, was associated with reduced allograft rejection risks and demonstrated noninferiority to patients without reflux. A standardized peri-transplant test-and-treat algorithm may guide timely reflux management to improve lung transplant outcomes.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Current views on chronic rejection after lung transplantation
    Verleden, Geert M.
    Vos, Robin
    Vanaudenaerde, Bart
    Dupont, Lieven
    Yserbyt, Jonas
    Van Raemdonck, Dirk
    Verleden, Stijn
    TRANSPLANT INTERNATIONAL, 2015, 28 (10) : 1131 - 1139
  • [22] Surveillance for acute cellular rejection after lung transplantation
    Greer, Mark
    Werlein, Christopher
    Jonigk, Danny
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [23] From acute to chronic rejection after kidney transplantation
    Arns, W
    Weber, M
    MEDIZINISCHE KLINIK, 2002, 97 (10) : 609 - 613
  • [24] Antireflux surgery versus medical management of gastro-oesophageal reflux after lung transplantation
    Razia, Deepika
    Mittal, Sumeet K.
    Fournier, Sarah
    Walia, Rajat
    Smith, Michael A.
    Bremner, Ross M.
    Huang, Jasmine L.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023, 63 (03)
  • [25] Everolimus as a treatment of Chronic Lung Alograft Rejection (CLAD) in lung transplantation
    Iturbe Fernandez, David
    De Pablo Gafas, Alicia
    Escobar Ramirez, Karla Fabiola
    Ruiz Sainz, Fatima
    Perez Gonzalez, Virginia
    Mora Cuesta, Victor Manuel
    Fernandez Rozas, Sonia Maria
    Alonso Moralejo, Rodrigo
    Cifrian Martinez, Jose Manuel
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [26] ABNORMAL BOLUS REFLUX WITH NORMAL ACID REFLUX IS ASSOCIATED WITH GREATER RISK OF CHRONIC REJECTION AFTER LUNG TRANSPLANTATION THAN NORMAL BOLUS REFLUX WITH ABNORMAL ACID REFLUX
    Lo, Wai-Kit
    Goldberg, Hilary J.
    Chan, Walter W.
    GASTROENTEROLOGY, 2020, 158 (06) : S1067 - S1067
  • [27] Ursodeoxycholic acid may reduce acute rejection after heart transplantation
    Bahrle, S
    Szabo, G
    Stiehl, A
    Theilmann, L
    Dengler, TJ
    Zimmermann, R
    CIRCULATION, 1996, 94 (08) : 307 - 307
  • [28] Cyclophosphamide rescue therapy for chronic rejection after lung transplantation
    Verleden, GM
    Buyse, B
    Delcroix, M
    Fabri, R
    Vanhaecke, J
    Van Raemdonck, D
    Lerut, T
    Demedts, M
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (11): : 1139 - 1142
  • [29] Acute rejection on immune-mediated chronic rejection after liver transplantation
    D'Ambrosio, Daria
    Tavano, Daniele
    Lattanzi, Barbara
    Dei Malatesta, Marialuisa Framarino
    De Goyet, Jean De Ville
    Corsi, Alessandro
    Mitterhofer, Anna Paola
    Corradini, Stefano Ginanni
    Mennini, Gianluca
    Rossi, Massimo
    Merli, Manuela
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2021, 180 (04) : 136 - 143
  • [30] Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation
    Naik, Chetan
    Moore, Cody
    Pipeling, Matthew
    D'Cunha, Jonathan
    Ruppert, Kristine
    Ensor, Christopher
    Morrell, Matthew
    TRANSPLANTATION DIRECT, 2018, 4 (05):